What's Going On With Novavax Stock On Friday?

Novavax Inc. (NASDAQ:NVAX) shares are down on Friday, possibly on profit-taking after the stock rallied on Thursday following the company's announcement of its fourth-quarter and full-year 2025 financial results.

It is worth noting that Novavax has a short interest of 31.41% of its float.

Novavax Q4 Profit Shift

Novavax reported a fourth-quarter earnings shift to a profit of 11 cents, compared to a loss of 51 cents a year ago, with revenue hitting $147 million, a 67% increase year-over-year.

However, the company also projected adjusted total revenue for 2026 between $230 million and $270 million, falling short of the consensus estimate of $381.22 million.

In addition, the company announced it expects Non-GAAP R&D and SG&A expenses of $325 million in 2026, $225 million in 2027, and $200 million or less in 2028.

This news follows Novavax’s achievement of key milestones under its Sanofi SA (NASDAQ:SNY) agreement and progress towards new partnerships, but the revenue forecast has overshadowed these developments.

Novavax Shows Short-Term Strength Amid Downturn

Currently, Novavax is trading 8.4% above its 20-day simple moving average (SMA) and 9.2% above its 100-day SMA, indicating some short-term strength despite the recent downturn.

Over the past 12 months, shares have shown significant growth and are currently positioned closer to their 52-week highs than lows.

The RSI is at 44.45, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, MACD data is not available, but the absence of significant crossovers indicates a stable trend without immediate bullish or bearish pressure.

The combination of neutral RSI and the lack of a MACD signal suggests mixed momentum, indicating that traders should watch for potential breakout or reversal signals in the near term.

• Key Resistance: $11.50
• Key Support: $9.00

Analyst Consensus & Recent Actions: The stock carries a Hold Rating with an average price target of $32.62. Recent analyst moves include:

• HC Wainwright & Co.: Buy (Raises Target to $16.00) (Feb. 27)

NVAX Price Action: Novavax shares were down 11.30% at $9.93 at the time of publication on Friday, according to Benzinga Pro data.

Photo via Shutterstock